DEAL: Enyo Pharma raises €40M
04 Juin 2018
Enyo Pharma, a clinical stage biotech company developing innovative drug candidates by mimicking virus strategies to modulate host cellular functions, today announced that it has completed a €40 million Series B round of financing from US and European investors. This new funding will enable the company to finance the two first Phase II clinical trial. A second asset is also planned to enter clinic by 2019.
EXPEN is advisor to the transaction.
To get more information about the deal: click here.